A Case Study of Symptoms Experienced following the Administration of Erlotinib

2.50
Hdl Handle:
http://hdl.handle.net/10755/164620
Category:
Abstract
Type:
Presentation
Title:
A Case Study of Symptoms Experienced following the Administration of Erlotinib
Author(s):
Whitmer, Kura; Braford, Brian; Gholz, Ruth; Pancoast, John; Sullivan, David; Sommers, Marilyn
Author Details:
Kura Whitmer, PhD, RN, Assoc. Prof. at University of Cincinnati, Cincinnati, Ohio, USA, email: kyra.whitmer@uc.edu; Brian Braford, PhD, BCC Group, Cincinnati, Ohio; Ruth Gholz, RN, MS, AOCN, VA Med. Ctr., Cincinnati, Ohio; John Pancoast, MD, VA Med. Ctr., Cincinnati, Ohio; David Sullivan, BCC Group, Cincinnati, OH; Marilyn Sommers, PhD, RN, FAAN, U. of Pennsylvania, Philadelphia
Abstract:
Research Study: Eighty percent of those receiving Erlotinib for treatment of cancer will develop a facial rash that is distressing both physically and psychosocially. This rash has been described but not quantified nor have the accompanying symptoms been quantified. To develop measurement strategies to quantify the degree of skin involvement through digital image analysis and to quantify accompanying non-dermatologic symptoms. This study addresses the ONS Research Agenda, cancer symptoms and their management. The conceptual framework underpinning this research is based on the physics of light and on the L*a*b* color space in particular. Armstrong's model of Symptom Experience provided an explanation for antecedents to the perception of symptoms, followed by consequences. Digital images were corrected for brightness and white balance before transformation into luminance and chrominance representation by converting them to the L*a*b* color space (L*- lightness-darkness; a*- redness-greenness; b* yellowness-blueness). The a* component image was saved as a grayscale image. We used ImageJ to obtain a histogram of erythema and the intensity of the erythema. The following self reported questionnaires were used to quantify accompanying symptoms, their intensity, distress and impact: Skin Questionnaire, Symptom Assessment Scale, Distress Thermometer, and FACT-G. Data were collected prior to the initiation of Traceva and weekly until the rash stabilized. Rash erythema was quantified weekly for 8 weeks. Accompanying symptoms had an interdependent pattern. Nursing interventions, including the use of moisturizers, Diphenhydramine and Minocycline, lessened the distress experienced. When both patient and caregiver anticipate the symptom experience, it can be managed so that the therapeutic effect of Erlotinib can occur.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2009
Conference Name:
34th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
San Antonio, Texas, USA
Sponsors:
Funding Source: Supported by ONF Symptom Management Research Grant, 2005
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleA Case Study of Symptoms Experienced following the Administration of Erlotiniben_GB
dc.contributor.authorWhitmer, Kuraen_US
dc.contributor.authorBraford, Brianen_US
dc.contributor.authorGholz, Ruthen_US
dc.contributor.authorPancoast, Johnen_US
dc.contributor.authorSullivan, Daviden_US
dc.contributor.authorSommers, Marilynen_US
dc.author.detailsKura Whitmer, PhD, RN, Assoc. Prof. at University of Cincinnati, Cincinnati, Ohio, USA, email: kyra.whitmer@uc.edu; Brian Braford, PhD, BCC Group, Cincinnati, Ohio; Ruth Gholz, RN, MS, AOCN, VA Med. Ctr., Cincinnati, Ohio; John Pancoast, MD, VA Med. Ctr., Cincinnati, Ohio; David Sullivan, BCC Group, Cincinnati, OH; Marilyn Sommers, PhD, RN, FAAN, U. of Pennsylvania, Philadelphiaen_US
dc.identifier.urihttp://hdl.handle.net/10755/164620-
dc.description.abstractResearch Study: Eighty percent of those receiving Erlotinib for treatment of cancer will develop a facial rash that is distressing both physically and psychosocially. This rash has been described but not quantified nor have the accompanying symptoms been quantified. To develop measurement strategies to quantify the degree of skin involvement through digital image analysis and to quantify accompanying non-dermatologic symptoms. This study addresses the ONS Research Agenda, cancer symptoms and their management. The conceptual framework underpinning this research is based on the physics of light and on the L*a*b* color space in particular. Armstrong's model of Symptom Experience provided an explanation for antecedents to the perception of symptoms, followed by consequences. Digital images were corrected for brightness and white balance before transformation into luminance and chrominance representation by converting them to the L*a*b* color space (L*- lightness-darkness; a*- redness-greenness; b* yellowness-blueness). The a* component image was saved as a grayscale image. We used ImageJ to obtain a histogram of erythema and the intensity of the erythema. The following self reported questionnaires were used to quantify accompanying symptoms, their intensity, distress and impact: Skin Questionnaire, Symptom Assessment Scale, Distress Thermometer, and FACT-G. Data were collected prior to the initiation of Traceva and weekly until the rash stabilized. Rash erythema was quantified weekly for 8 weeks. Accompanying symptoms had an interdependent pattern. Nursing interventions, including the use of moisturizers, Diphenhydramine and Minocycline, lessened the distress experienced. When both patient and caregiver anticipate the symptom experience, it can be managed so that the therapeutic effect of Erlotinib can occur.en_GB
dc.date.available2011-10-27T12:04:00Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:04:00Z-
dc.conference.date2009en_US
dc.conference.name34th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationSan Antonio, Texas, USAen_US
dc.description.sponsorshipFunding Source: Supported by ONF Symptom Management Research Grant, 2005-
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.